Psychedelic Bulletin #106 – DMT Study Skips Set and Setting; Cybin Acquires Phase 1 Study; FDA Snubs Seamless Trial Design

This Week: DMT Study Skips Set and Setting Cybin Acquires Entheon’s Phase 1 DMT Study FDA Snubs Mydecine’s Seamless Trial Design Eleusis Scraps SPAC and more… DMT Study Skips Set and Setting This week we take a closer look at a recent publication out of Yale and VA Connecticut Healthcare System. This exploratory study sought to ascertain the safety, tolerability and efficacy of DMT in a small…

Source